Nuclear Medicine and Molecular Imaging

  • 제42권6호
  • /
  • Pages.425-434
  • /
  • 2008
  • /
  • 1869-3474(pISSN)
  • /
  • 1869-3482(eISSN)
대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

도파민 운반체 영상의 임상이용을 위한 실제적 접근

Practical Approach for the Clinical Use of Dopamine Transporter Imaging

  • 김재승 (울산의대 서울아산병원 핵의학과)
  • Kim, Jae-Seung (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 발행 : 2008.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Dopamine transporter imaging is useful in the diagnosis of Parkinson's disease and the most successful technique in the clinical use of neuroreceptor imaging. Recently, several radiopharmaceuticals including I-123 FP-CIT, Tc-99m TRODAT, and F-18 FP-CIT for dopamine transporter imaging have been approved for the routine clinical use in several European countries, Taiwan and Korea, respectively. This review summarized the practical issue for the routine clinical examination of dopamine transporter imaging.

키워드

참고문헌

  1. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991;9:43-9 https://doi.org/10.1002/syn.890090107
  2. Niznik HB, Fogal EF, Fassos FF, Seaman P. The dopamine transporter is absent in Parkinsonian putamen and reduced in the caudate nucleus. Neurochem 1991;56:192-8 https://doi.org/10.1111/j.1471-4159.1991.tb02580.x
  3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-55 https://doi.org/10.1016/0022-510X(73)90175-5
  4. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using singlephoton emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171-82 https://doi.org/10.1007/s002590050374
  5. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-23 https://doi.org/10.1002/mds.10592
  6. Aquilonius SM, Bergstrom K, Eckernas SA, Hartviq P, Leenders KL, Lundquist H, et al. In vivo evaluation of striatal dopamine reuptake site $^{11}C-nomifensine$ and positron emission tomography. Acta Neurol Scand 1987;76:283-7 https://doi.org/10.1111/j.1600-0404.1987.tb03582.x
  7. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47: 1290-8 https://doi.org/10.1001/archneur.1990.00530120034007
  8. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Darqham A, Wallace E, et al. single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993;90:11965-9 https://doi.org/10.1073/pnas.90.24.11965
  9. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, et al. Positron emission tomographic imaging of the dopamine transporter with [$^{11}C$]WIN35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34: 423-31 https://doi.org/10.1002/ana.410340331
  10. Muller L, Halldin C, Farde L, Karlsson P, Hall H, Swahn CG, et al. [$^{11}C]{\beta}-CIT$, a cocaine analog preparation autoradiography and preliminary PET investigations. Nucl Med Biol 1993;20: 249-55 https://doi.org/10.1016/0969-8051(93)90045-V
  11. Neuromeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, et al. N-w-Fluoroalkyl analogs of $2{\beta}-carbomethoxy- 3{\beta}-(4-iodophenyl)tropane$ (${\beta}-CIT$): radiotracers for PET and SPECT imaging of dopamine transporters. J Med Chem 1994; 37:1558-61 https://doi.org/10.1021/jm00037a004
  12. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, et al. Decreased single-photon emission computed tomographic [$^{123}I$]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98 https://doi.org/10.1002/ana.410380407
  13. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoqhbi SS, Baldwin RM, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of ${\beta}-CIT$. J Nucl Med 1996;37:1129-33
  14. Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl JR, et al. Radiosynthesis of [$^{18}F$] $N-3-fluoroporpyl-2-{beta}-carbomethoxy-3-{beta}-(4-iodophenyl)$ nortropane and the first human study with PET. Nucl Med Biol 1996;23:999-1004 https://doi.org/10.1016/S0969-8051(96)00155-2
  15. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med 1996;23:1527-30 https://doi.org/10.1007/BF01254479
  16. Lundkvist C, Haldin C, Ginovart N, Swahn CG, Farde L. $^{18}F-CIT-FP$ is superior to 11C-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol 1997;24:621-7 https://doi.org/10.1016/S0969-8051(97)00077-2
  17. Guttman M, Burkholder J, Kish SJ, Hussev D, Wilson A, DaSilva J, et al. [$^{11}C$]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-83 https://doi.org/10.1212/WNL.48.6.1578
  18. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [$^{123}T$]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62: 133-40 https://doi.org/10.1136/jnnp.62.2.133
  19. Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [$^{18}F$]beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:737-41 https://doi.org/10.1136/jnnp.67.6.737
  20. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using singlephoton emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171-82 https://doi.org/10.1007/s002590050374
  21. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [$^{128}I$]-FP-CIT SPECT imaging: the [$^{128}T$]-FP-CIT study group. Mov Disord 2000;15: 503-10 https://doi.org/10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V
  22. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-25 https://doi.org/10.1001/archneur.61.6.919
  23. Choi SR, Kung MP, Plossl K, Meegalla S, Kung HF. An improved kit formulation of a dopamine transporter imaging agent: [Tc-99m]TRODAT-1. Nucl Med Biol 1999;26:461-6 https://doi.org/10.1016/S0969-8051(99)00010-4
  24. Okada T, Fujita M, Shimada S, Sato K, Schloss P, Watanabe Y, et al. Assessment of affinities of beta-CIT, beta-CIT-FE, and beta-CIT-FP for monoamine transporters permanently expressed in cell lines. Nucl Med Biol 1998;25:53-8 https://doi.org/10.1016/S0969-8051(97)00156-X
  25. Scheffel U, Lever JR, Abraham P, Parham KR, Mathews WB, Kopajtic T, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse 1997;25:345-9 https://doi.org/10.1002/(SICI)1098-2396(199704)25:4<345::AID-SYN5>3.0.CO;2-A
  26. Ritz MC, Cone EJ, Kuhar MJ. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 1990;46:635-45 https://doi.org/10.1016/0024-3205(90)90132-B
  27. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [$N-^{11}C-methyl]-(-)- cocaine$ PET studies in human subjects. J Cereb Blood Flow Metab 1990;10(5):740-7 https://doi.org/10.1038/jcbfm.1990.127
  28. Telang FW, Volkow ND, Levy A, Logan J, Fowler JS, Felder C, et al. Distribution of tracer levels of cocaine in the human brain as assessed with averaged [$^{11}C$] cocaine images. Synapse 1999;31(4):290-6 https://doi.org/10.1002/(SICI)1098-2396(19990315)31:4<290::AID-SYN7>3.0.CO;2-G
  29. Gatley SJ, Ding YS, Volkow ND, Chen R, Sugano Y, Fowler JS. Binding of d-threo-[$^{11}C$]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Eur J Pharmacol 1995;281:141-9 https://doi.org/10.1016/0014-2999(95)00233-B
  30. Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, et al. N-substituted analogs of 2 beta-carbomethoxy-3 beta-(4'-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 1996;39:543-8 https://doi.org/10.1021/jm9505324
  31. Madras BK, Meltzer PC, Liang AY, Elmaleh DR, Babich J, Fischman AJ. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 1998; 29: 93-104 https://doi.org/10.1002/(SICI)1098-2396(199806)29:2<93::AID-SYN1>3.0.CO;2-5
  32. Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, et al. [$^{11}C$]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 2003;30:1220-30 https://doi.org/10.1007/s00259-003-1212-3
  33. Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [$^{123}I$] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9-24
  34. Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, et al. Voxel-wise analysis of [$^{123}I$]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005;128(Pt 7):1605-12 https://doi.org/10.1093/brain/awh485
  35. Seppi K, Scherfler C, Donnemiller E, Virgolini I, Schocke MF, Goebel G, et al. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [$^{123}I$]beta-CIT SPECT analysis. Arch Neurol 2006;63(8):1154-60 https://doi.org/10.1001/archneur.63.8.1154
  36. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med 1998;39:1521-30
  37. Rinne JO, Laihinen A, Nagren K, Ruottinen H, Ruotsalainen U, Rinne UK. PET examination of the monoamine transporter with [$^{11}C]{\beta}-CIT$ and [$^{11}C]{\beta}-CFT$ in early Parkinson's disease. Synapse 1995;21:97-103 https://doi.org/10.1002/syn.890210202
  38. Kim DW, Ahn DS, Oh YH, Lee S, Kil HS, Oh SJ, et al. A new class of $S_N2$ reactions catalyzed by protic solvents: Facile fluorination for isotopic labeling of diagnostic molecules. J Am Chem Soc 2006;128:16394-7 https://doi.org/10.1021/ja0646895
  39. Bergstrom KA, Halldin C, Lundkvist C, Swahn CG, Akerman KK, Kuikka JT, et al. Characterization of C-11 or I-123 labelled ${\beta}-CIT-FP$ and ${\beta}-CIT-FE$ metabolism measured in monkey and human plasma. Identification of two labeled metabolites with HPLC. Hum Psychopharmacol 1996;11:483-90
  40. Ichise M, Meyer JH, Yonekura Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 2001; 42:755-63
  41. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Graphical, kinetic, and equilibrium analyses of in vivo $[^{123}I]{/beta}-CIT$ binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1993;13:24-42 https://doi.org/10.1038/jcbfm.1993.6
  42. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratio without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-40 https://doi.org/10.1097/00004647-199609000-00008
  43. Ichise M, Toyama H, Innis RB, Carson RE. strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Metab 2002;22:1271-81 https://doi.org/10.1097/01.WCB.0000038000.34930.4E
  44. Slifstein M, Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med 2000;41: 2083-8
  45. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to [$^{11}C$]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003;23:1096-112 https://doi.org/10.1097/01.WCB.0000085441.37552.CA
  46. Laruelle M. The role of model-based methods in the development of single scan techniques. Nucl Med Biol 2000;27:637-42 https://doi.org/10.1016/S0969-8051(00)00142-6
  47. Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [^{123}I$]FPCIT SPECT. J Nucl Med 1999;40:753-61
  48. Yaqub M, Boellaard R, van Berckel BN, Ponsen MM, Lubberink M, Windhorst AD, et al. Quantification of dopamine transporter binding using [$^{18}F]FP-b-CIT$ and positron emission tomography. J Cereb Blood Flow Metab 2007;27:1397-406 https://doi.org/10.1038/sj.jcbfm.9600439
  49. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observerindependent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005;46:1109-18
  50. Kas A, Payoux P, Habert MO, Malek Z, Cointepas Y, El Fakhri G, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of $^{123}I-FP-CIT$ images. J Nucl Med 2007;48:1459-67 https://doi.org/10.2967/jnumed.106.038646
  51. Ma Y, Mentis DM, Chaly T, Spetsieris PG, Eidelberg D. Parametric mapping of [^{18}F]FPCIT$ binding in early stage Parkinson's disease: a PET study. Synapse 2002;45:125-33 https://doi.org/10.1002/syn.10090
  52. Booij J, Kemp P. Dopamine transporter imaging with [$^{123}$I]FPCIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35:424-38
  53. Lees AJ. Drugs for Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:607-10 https://doi.org/10.1136/jnnp.73.6.607
  54. Winogrodzka A, Booij J, Wolters ECh. Disease-related and drug induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease. Parkinsonism Relat Disord 2005; 11:475-84 https://doi.org/10.1016/j.parkreldis.2005.08.001
  55. Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with $^{123}I-FP-CIT$ in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 2005;32:1452-6 https://doi.org/10.1007/s00259-005-1922-9
  56. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508 https://doi.org/10.1056/NEJMoa033447
  57. Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment with L-dopa/carbidopa or Lselegiline on striatal dopamine transporter SPECT imaging with $^{[123}I]{\beta}-CIT$. Mov Disord 1999;14:436-42 https://doi.org/10.1002/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J
  58. Fowler JS, Volkow ND, Logan J, Franceschi D, Wang GJ, MacGregor R, et al. Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci 2001;68:2759-68 https://doi.org/10.1016/S0024-3205(01)01079-7
  59. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. $[^{123}I]{\beta}-CIT$ SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:294-8 https://doi.org/10.1136/jnnp.74.3.294
  60. Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-6 https://doi.org/10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y
  61. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-64 https://doi.org/10.1212/WNL.56.11.1559
  62. Gordon I, Weizman R, Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996;298:27-30 https://doi.org/10.1016/0014-2999(95)00770-9
  63. Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with $^{123}I-FP-CIT$ SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: A double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007;48: 359-66
  64. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, et al. SPECT imaging of dopamine and serotonin transporters with $[^{123}I]{\beta}-CIT$: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309 https://doi.org/10.1002/syn.890130402
  65. Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 2003;34:77-80 https://doi.org/10.1055/s-2003-39602
  66. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001;158:377-82 https://doi.org/10.1176/appi.ajp.158.3.377
  67. Chou YH, Huang WS, Su TP, Lu RB, Wan FJ, Fu YK. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: a SPECT study. Eur Neuropsychopharmacol 2007;17:46-52 https://doi.org/10.1016/j.euroneuro.2006.05.002
  68. Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-95 https://doi.org/10.1176/appi.ajp.163.3.387
  69. Fearnley J, Lees A. Aeging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301 https://doi.org/10.1093/brain/114.5.2283
  70. Ma ST, Rinne JO, Collan Y, Roytta M, Rinne UK. A quantitative morpholmetrical study of neuron degeneration in the substantia nigra in Parkinson's disease. J neurol Sci 1996;140: 40-5 https://doi.org/10.1016/0022-510X(96)00069-X
  71. Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with $^{123}I-B-CIT SPECT: Binding kinetics and effects of normal aging. J Nucl Med 2000;41:36-44
  72. Mozley PD, Acton PD, Barraclough ED, Plossl K, Gur RC, Alavi A, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med 1999;40:1812-7
  73. Lavalaye J, Booij J, Reneman L, Habraken JBA, van Royen EA. Effect of age and gender on dopamine transporter imaging with $[^{123}I]FP-CIT$ SPET in healthy volunteers. Eur J Nucl Med 2000; 27:867-9 https://doi.org/10.1007/s002590000279
  74. Leroy C, Comtat C, Trebossen R, Syrota A, Martinot J-L, Ribeiro M-J. Assessment of $^{11}C-PE2I$ Binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J Nucl Med